Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


St. John's Wort Tolerance Superior To Rx Imipramine - German Study

This article was originally published in The Tan Sheet

Executive Summary

St. John's wort is more easily tolerated by patients than the Rx antidepressant imipramine, according to a study published in the Sept. 2 British Medical Journal.

You may also be interested in...

St. John's Wort/HIV Protease Inhibitor Use Warnings Issued By FDA, NIH

HIV patients taking protease inhibitors should avoid taking St. John's wort dietary supplements, FDA and the National Institutes of Health warned Feb. 10, following the release of study results demonstrating the herbal compromises the antiviral drugs' effectiveness.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts